z-logo
open-access-imgOpen Access
Interleukin-37 Enhances the Suppressive Activity of Naturally Occurring CD4+CD25+ Regulatory T Cells
Author(s) -
Dawei Wang,
Ning Dong,
Yao Wu,
Xiaomei Zhu,
Chunting Wang,
YongMing Yao
Publication year - 2016
Publication title -
scientific reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.24
H-Index - 213
ISSN - 2045-2322
DOI - 10.1038/srep38955
Subject(s) - il 2 receptor , foxp3 , immune system , immunology , interleukin , cytotoxic t cell , cytokine , medicine , biology , t cell , biochemistry , in vitro
Naturally occurring CD4 + CD25 + regulatory T cells (Tregs) are essential for the suppression of autoimmunity and can control the immune-mediated pathology during the early phase of sepsis. Our previous data showed that silencing interleukin-37 (IL-37) in human CD4 + CD25 + Tregs obviously reduced the suppressive activity of CD4 + CD25 + Tregs. Here, we found that rhIL-37 stimulation markedly enhanced the suppressive activity of CD4 + CD25 + Tregs isolated from naive C57BL/6 J mice in the absence or presence of lipopolysaccharide (LPS). Treatment with rhIL-37 could significantly upregulate the expression of cytotoxic T-lymphocyte-associated antigen (CTLA)-4 and forkhead/winged helix transcription factor p3 (Foxp3) on CD4 + CD25 + Tregs. Also, rhIL-37 stimulation promoted the production of transforming growth factor-β1 (TGF-β1) but not IL-10 in the supernatants of cultured CD4 + CD25 + Tregs. Pretreated CD4 + CD25 + Tregs with rhIL-37 in the presence or absence of LPS were cocultured with CD4 + CD25 − T cells, ratio of IL-4/interferon-γ in the supernatants obviously increased in IL-37-stimulated groups. In addition, early administration of IL-37 significantly improved the survival rate of septic mice induced by cecal ligation and puncture. Taken together, we concluded that rhIL-37 enhances the suppressive activity of CD4 + CD25 + Tregs and might be a potential immunomodulator for the treatment of septic complications.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here